Coloplast completed the acquisition of Kerecis for $1.3bn.

Coloplast, a manufacturer of medical devices, completed the acquisition of Kerecis, a biotechnology company pioneering the use of fish skin, for $1.3bn. “I am very excited to welcome the Kerecis team into the Coloplast family. Both Coloplast and Kerecis are on a mission to help many more patients in need of advanced wound treatment, and I look forward to continuing the growth and profitability journey, as we build a truly global wound care franchise together,” Kristian Villumsen, Coloplast President and CEO.